A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever

Thomas E. Van Metre, N Franklin Adkinson, Frank J. Amodio, Anne Kagey-Sobotka, Lawrence M. Lichtenstein, Michael R. Mardiney, Philip S. Norman, Gary L. Rosenberg

Research output: Contribution to journalArticle

Abstract

In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) and with placebo (11 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p <0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo group and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.

Original languageEnglish (US)
Pages (from-to)181-193
Number of pages13
JournalThe Journal of Allergy and Clinical Immunology
Volume69
Issue number2
DOIs
StatePublished - 1982

Fingerprint

Seasonal Allergic Rhinitis
Ambrosia
Immunotherapy
Appointments and Schedules
Injections
Placebos
Immunoglobulin E
Therapeutics
ragweed pollen
Treatment Failure
Immunoglobulin G

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Van Metre, T. E., Adkinson, N. F., Amodio, F. J., Kagey-Sobotka, A., Lichtenstein, L. M., Mardiney, M. R., ... Rosenberg, G. L. (1982). A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. The Journal of Allergy and Clinical Immunology, 69(2), 181-193. https://doi.org/10.1016/0091-6749(82)90098-7

A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. / Van Metre, Thomas E.; Adkinson, N Franklin; Amodio, Frank J.; Kagey-Sobotka, Anne; Lichtenstein, Lawrence M.; Mardiney, Michael R.; Norman, Philip S.; Rosenberg, Gary L.

In: The Journal of Allergy and Clinical Immunology, Vol. 69, No. 2, 1982, p. 181-193.

Research output: Contribution to journalArticle

Van Metre, Thomas E. ; Adkinson, N Franklin ; Amodio, Frank J. ; Kagey-Sobotka, Anne ; Lichtenstein, Lawrence M. ; Mardiney, Michael R. ; Norman, Philip S. ; Rosenberg, Gary L. / A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. In: The Journal of Allergy and Clinical Immunology. 1982 ; Vol. 69, No. 2. pp. 181-193.
@article{a9e56fc0ae044fa2a5553c9db04998dd,
title = "A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever",
abstract = "In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) and with placebo (11 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p <0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo group and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.",
author = "{Van Metre}, {Thomas E.} and Adkinson, {N Franklin} and Amodio, {Frank J.} and Anne Kagey-Sobotka and Lichtenstein, {Lawrence M.} and Mardiney, {Michael R.} and Norman, {Philip S.} and Rosenberg, {Gary L.}",
year = "1982",
doi = "10.1016/0091-6749(82)90098-7",
language = "English (US)",
volume = "69",
pages = "181--193",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever

AU - Van Metre, Thomas E.

AU - Adkinson, N Franklin

AU - Amodio, Frank J.

AU - Kagey-Sobotka, Anne

AU - Lichtenstein, Lawrence M.

AU - Mardiney, Michael R.

AU - Norman, Philip S.

AU - Rosenberg, Gary L.

PY - 1982

Y1 - 1982

N2 - In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) and with placebo (11 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p <0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo group and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.

AB - In 44 patients highly sensitive to ragweed, we compared weekly injections of single doses of ragweed extract (RW-Wk, 15 patients) with clustered doses of ragweed extract at 3-wk intervals (RW-Cl, 18 patients) and with placebo (11 patients) for effects on ragweed hay fever symptom-medication scores and immunologic variates. Patients were matched and randomly assigned to treatment groups. Ragweed doses were advanced to the highest tolerated dose. Doses and number of visits were lower in the RW-Cl group than in the RW-Wk group. Despite lower doses, systemic reactions were not reduced and antiragweed IgE levels increased significantly more in the RW-Cl group than those in the RW-Wk group. Both the RW-Cl and RW-Wk groups had significant increases in antiragweed IgG levels, decreases in seasonal rise in antiragweed IgE levels, and lower symptom-medication scores (p <0.01) in comparison with the placebo group. We conclude that the RW-Cl regimen offered no important advantage over RW-Wk. Seventeen patients had previously received Rinkel-method immunotherapy with 0.5 ml of end-point dilution of ragweed extract for 1 to 2 yr without significant clinical improvement or immunologic changes. After adequate treatment with either RW-Wk or RW-Cl, these patients had significantly lower symptom-medication scores than those of the placebo group and immunologic changes similar to those of the entire active-treatment group. Therefore, treatment failures on Rinkel immunotherapy respond well to adequate dose immunotherapy by either schedule.

UR - http://www.scopus.com/inward/record.url?scp=0020059768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020059768&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(82)90098-7

DO - 10.1016/0091-6749(82)90098-7

M3 - Article

C2 - 7056949

AN - SCOPUS:0020059768

VL - 69

SP - 181

EP - 193

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -